---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Treatment combinations, and Treatment duration. Questions: What is the Kisqali dose for metastatic breast cancer? How are the aromatase inhibitor and fulvestrant given with Kisqali? How long do patients take Kisqali for metastatic breast cancer? How is the Kisqali dose lowered to manage side effects? 3 further questions follow. 7 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Dosing and administration questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Dosing and administration questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications: Dosing and administration](https://www.evicenter.com/medical-information/kisqali/dosing-and-administration).

## Dosing

<a id="kisqali-dose"></a>

### What is the Kisqali dose for metastatic breast cancer?

> “For patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), the starting dose for KISQALI<sup>®</sup> (ribociclib) is 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off), in combination with an aromatase inhibitor (AI) or fulvestrant.”

Source: [KISQALI: Dosing | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dosing#:~:text=For%20patients%20with%20hormone%20receptor%2Dpositive%2Fhuman,aromatase%20inhibitor%20%28AI%29%20or%20fulvestrant.)

> “The recommended dosage of KISQALI is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 
> consecutive days followed by 7 days off in 28-day treatment cycles. KISQALI should be given in combination with 
> endocrine therapy (fulvestrant or an aromatase inhibitor). Refer to the Full Prescribing Information for the recommended 
> dose of endocrine therapy.”

Source: [KISQALI: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=3)

<a id="kisqali-dose-reductions"></a>

### How is the Kisqali dose lowered to manage side effects?

> “Dose adjustments for adverse reactions should be made in a stepwise order by reducing the number of tablets taken to 2 x 200-mg tablets or 1 x 200-mg tablet.<sup>1</sup>
>
> If dose reduction below 200 mg/day is required, discontinue treatment<sup>1</sup>”

Source: [KISQALI: Dose Adjustments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dose-adjustments#:~:text=Dose%20adjustments%20for%20adverse%20reactions,200%20mg%2Fday%20is%20required%2C%20discontinue)

> “Advanced or metastatic breast cancer 
> Starting dose 
> 600 mg/day 
> three 200 mg tablets 
> First dose reduction 
> 400 mg/day 
> two 200 mg tablets 
> Second dose reduction 
> 200 mg/day* 
> one 200 mg tablet 
> *If dose reduction below 200 mg/day is required, discontinue KISQALI.”

Source: [KISQALI: Prescribing information, page 4, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=4)

Note: The second passage is the advanced or metastatic breast cancer section of Table 1 of the Prescribing Information; each dose level is followed by its number of 200 mg tablets.

<a id="kisqali-qt-dose-adjustment"></a>

### How is the Kisqali dose adjusted for QT prolongation?

> “QTcF prolongation
> >480 ms and ≤500 ms
>
>
>
> Interrupt treatment until recovery to ≤480 ms; resume at next lower dose level
>
> If QTcF >480 ms recurs, interrupt dose until recovery; resume at next lower dose level 
>
>
>
>
> QTcF prolongation >500 ms
>
>
>
> Interrupt treatment until recovery to ≤480 ms; resume at next lower dose level
>
> If QTcF >500 ms recurs, discontinue KISQALI
>
> Permanently discontinue KISQALI if QTcF interval prolongation is either >500 ms or >60 ms change from baseline AND associated with torsades de pointes, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia”

Source: [KISQALI: Dose Adjustments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dose-adjustments#:~:text=QTcF%20prolongation,or%20signs%2Fsymptoms%20of%20serious%20arrhythmia)

On the page, select: QT PROLONGATION

> “ECGs should be assessed prior to initiation of treatment. Initiate treatment with KISQALI only in patients with QTcF values less than 450 ms. Repeat ECGs at approximately Day 14 of the first cycle and as clinically indicated. In case of QTcF prolongation at any given time during treatment, more frequent ECG monitoring is recommended”

Source: [KISQALI: Dose Adjustments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dose-adjustments#:~:text=ECGs%20should%20be%20assessed%20prior,frequent%20ECG%20monitoring%20is%20recommended)

On the page, select: QT PROLONGATION

<a id="kisqali-liver-dose-adjustment"></a>

### How is the Kisqali dose adjusted for elevated liver enzymes?

> “Grade 1 (> ULN - 3 × ULN) or grade 2 at baseline (>3 - 5 × ULN) 
>
>
>
> No dose adjustment required 
>
>
>
>
> New grade 2(>3 - 5 x ULN)
>
>
>
> Interrupt dose until recovery to ≤ baseline grade; resume at same dose level
>
> If grade 2 recurs, resume at next lower dose level 
>
>
>
>
> Grade 3(>5 - 20 x ULN)
>
>
>
> Interrupt dose until recovery to ≤ baseline grade; resume at next lower dose level
>
> If grade 3 recurs, discontinue 
>
>
>
>
> Grade 4 (>20 × ULN) or any grade with TB >2 × ULN without cholestasis
>
>
>
> Discontinue
>
>
>
>
> LFTs should be assessed prior to initiation of treatment. Repeat LFTs every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated. If grade ≥2 abnormalities are noted, more frequent monitoring is recommended”

Source: [KISQALI: Dose Adjustments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dose-adjustments#:~:text=Grade%201%20%28%3E%20ULN%20%2D,more%20frequent%20monitoring%20is%20recommended)

On the page, select: ALT AND/OR AST ELEVATION

<a id="kisqali-neutropenia-dose-adjustment"></a>

### How is the Kisqali dose adjusted for neutropenia?

> “Grade 1 or grade 2
> (ANC 1000/mm<sup>3</sup> - < LLN) 
>
>
>
> No dose adjustment required 
>
>
>
>
> Grade 3 (afebrile)
> (ANC 500/mm<sup>3</sup> - <1000/mm<sup>3</sup>)
>
>
>
> Interrupt dose until recovery to grade ≤2; resume at same dose level
>
> If grade 3 recurs, interrupt dose until recovery; resume at next lower dose level  
>
>
>
>
> Grade 3 (febrile)
> or grade 4 (ANC <500/mm<sup>3</sup>)  
>
>
>
> Interrupt dose until recovery to grade ≤2; resume at next lower dose level 
>
>
>
>
> Grade 3 febrile neutropenia is defined as a single episode of fever >38.3°C or ≥38°C for more than 1 hour and/or concurrent infection 
>
> CBCs should be assessed prior to initiation of treatment. Repeat CBCs every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated”

Source: [KISQALI: Dose Adjustments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dose-adjustments#:~:text=NEUTROPENIA-,Grade%201%20or%20grade%202,cycles%2C%20and%20as%20clinically%20indicated)

On the page, select: NEUTROPENIA

## Treatment combinations

<a id="kisqali-endocrine-partner-dosing"></a>

### How are the aromatase inhibitor and fulvestrant given with Kisqali?

> “KISQALI is given as 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) with either AI or fulvestrant<sup>1</sup>:
>
> AI should be taken once daily (continuously); in men and premenopausal women, an LHRH agonist should be administered according to current clinical practice guidelines”

Source: [KISQALI: Dosing | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dosing#:~:text=KISQALI%20is%20given%20as%20600,to%20current%20clinical%20practice%20guidelines)

> “Fulvestrant 500 mg should be administered intramuscularly on Days 1, 15, and 29, and once monthly thereafter; in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines”

Source: [KISQALI: Dosing | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dosing#:~:text=Fulvestrant%20500%20mg%20should%20be,to%20current%20clinical%20practice%20guidelines)

## Treatment duration

<a id="kisqali-treatment-duration"></a>

### How long do patients take Kisqali for metastatic breast cancer?

> “Patients should continue treatment until disease progression or unacceptable toxicity”

Source: [KISQALI: Dosing | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dosing#:~:text=Patients%20should%20continue%20treatment%20until%20disease%20progression%20or%20unacceptable%20toxicity)

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
